SYNTHETIC STUDIES ON TUMOR PROMOTERS & INHIBITORS

$718P41FY2009RRNIH

University Of California, San Francisco, San Francisco CA

Investigators

Linked publications & trials

Paper 34844857 Paper 33028660 Paper 31204099 Paper 29907569 Paper 29654160 Paper 29487104 Paper 28778876 Paper 28578850 Paper 27649525 Paper 27251789 Paper 27128997 Paper 27127798 Paper 27006500 Paper 26961658 Paper 26729708 Paper 26006010 Paper 25166742 Paper 25153195 Paper 24974296 Paper 24841206 Paper 24529992 Paper 24510890 Paper 24488826 Paper 24425750 Paper 24402695 Paper 24362263 Paper 24019147 Paper 23953109 Paper 23747011 Paper 23664614 Paper 23639431 Paper 23629657 Paper 23480256 Paper 23475669 Paper 23410521 Paper 23362256 Paper 23345524 Paper 23333304 Paper 23300442 Paper 23264352 Paper 23239825 Paper 23237383 Paper 23226976 Paper 23201124 Paper 23190395 Paper 23144648 Paper 23115187 Paper 23059470 Paper 23023596 Paper 22949553 Paper 22918439 Paper 22878499 Paper 22841314 Paper 22821268 Paper 22817900 Paper 22802652 Paper 22751498 Paper 22577016 Paper 22576084 Paper 22571327 Paper 22561460 Paper 22499768 Paper 22466421 Paper 22445341 Paper 22444582 Paper 22444387 Paper 22393263 Paper 22351294 Paper 22328712 Paper 22322595 Paper 22308409 Paper 22267324 Paper 22258260 Paper 22211580 Paper 22190037 Paper 22190034 Paper 22176556 Paper 22137581 Paper 22117532 Paper 22094702 Paper 22027198 Paper 21980548 Paper 21952759 Paper 21937731 Paper 21855796 Paper 21840988 Paper 21798377 Paper 21777475 Paper 21771977 Paper 21718766 Paper 21704604 Paper 21695130 Paper 21627121 Paper 21606357 Paper 21602791 Paper 21526149 Paper 21517887 Paper 21515758 Paper 21490164 Paper 21477079

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project is directed at five specific aims: D.1: The synthesis of gnidimacrin, a potent lead for the treatment of cancer based on PKC targeting;D.2: The development of a general and flexible rout to anticancer leads in the daphnane family and study of their activity;D.3: The synthesis and biological evaluation of daphnane-tigliane hybrids; D.4: The synthesis and biological evaluation of laulimalide analogs, compounds active against taxol resistant cancers; D.5: The design, synthesis, and evaluation of drug and probe transporters involving a real time bioluminescence assay with a specific focus on transporter conjugates that are designed for selective cell or tissue entry based on activation by extracellular proteases.

View original record on NIH RePORTER →